Joseph K Belanoff sold $3.0M of CORT
Chief Executive Officer at CORCEPT THERAPEUTICS INC. 40,000 shares at an average of $74.58, traded Nov 3, 2025, filed Nov 5, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.0M at market
- 0Share of holdings soldSold 1.4% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.3%, 3m -47.6%, 6m -32.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-267545, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 3, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -11,218 | $74.08 | $831k | 2,770,152 | Nov 5, 2025 |
| Nov 5, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -14,355 | $74.20 | $1.1M | 2,755,797 | Nov 5, 2025 |
| Nov 5, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -10,837 | $75.14 | $814k | 2,744,960 | Nov 5, 2025 |
| Nov 5, 2025 | SOpen-market sale Common Stockindirect: Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/0210b5-1 | -3,590 | $75.98 | $273k | 2,741,370 | Nov 5, 2025 |
Related signals
Other insiders at CORCEPT THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -242% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.2M 10,000 shares | -154% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $967k 8,333 shares | -68% | |
| 20Weak | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $30k 296 shares | -7% | |
| 35Weak | CORCEPT THERAPEUTICS INC | James N Wilson director | $1.1M 10,000 shares | -1% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.1M 10,000 shares | -64% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $6.5M 58,333 shares | -93% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -72% | |
| 60Notable | CORCEPT THERAPEUTICS INC | Kimberly Park director | $3.3M 26,685 shares | -100% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $3.9M 30,955 shares | -76% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.